A novel bispecific affitoxin simultaneously targeting E7 of HPV16/18 types: superior anti-tumor activity and EMT reversal in HPV-driven cervical cancer therapy
Sustained infection with high-risk HPV of the 16 and 18 types is accounted for nearly 75% of cervical cancer (CC), but now there is an absence of agents aimed at eradicating HPV infections. Notwithstanding, affibody-based affitoxins may represent a breakthrough in tumor-targeted therapy. Our previous work has constructed a bispecific affibody simultaneously targeting the early oncogenic proteins E7 of HPV16 and 18 types (named as Z Three forms of the affitoxin constructs (GrB-Z Two bispecific affitoxins of Z This work has developed a bispecific affitoxin that simultaneously targets HPV16- and HPV18-type CC cells, with a significant dual-functional advantage, combining the targeted inhibitory of the affibody with the cytotoxicity of the toxin molecule. Our research offers a novel design and approach for targeted therapy in HPV-driven cervical cancer.